Page last updated: 2024-08-25

methotrexate and Deafness, Transitory

methotrexate has been researched along with Deafness, Transitory in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (14.29)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (57.14)	24.3611
2020's	2 (28.57)	2.80

Authors

Authors	Studies
Cho, HH; Choi, Y; Lee, S; Umugire, A	1
Clay, S; Doss, J; Fang, Z; Moore, B; Musso, A; Norman, M; Prasad, P; Sheets, G; Tsien, F; Umrigar, A	1
Bagatell, R; Balamuth, N; Balis, F; Fox, E; Levin, K; Segers, B; Womer, R; Zhu, Y	1
Bruneau, B; Chappé, C; Gandemer, V; Robert, G; Taque, S	1
Ash, S; Cohen, IJ; Issakov, J; Kollender, Y; Shkalim-Zemer, V; Toledano, H; Yaniv, I	1
Grier, HE; Janeway, KA	1
Benesch, M; Kerbl, R; Lackner, H; Oberbauer, R; Pakisch, B; Schwinger, W; Urban, C	1

Reviews

1 review(s) available for methotrexate and Deafness, Transitory

Article	Year
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. The Lancet. Oncology, 2010, Volume: 11, Issue:7 Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Hearing Loss; Heart Diseases; Humans; Ifosfamide; Infertility; Kidney Diseases; Methotrexate; Neoplasms, Second Primary; Neurotoxicity Syndromes; Osteosarcoma; Survivors	2010

Article

Year

Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.

The Lancet. Oncology, 2010, Volume: 11, Issue:7

Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Hearing Loss; Heart Diseases; Humans; Ifosfamide; Infertility; Kidney Diseases; Methotrexate; Neoplasms, Second Primary; Neurotoxicity Syndromes; Osteosarcoma; Survivors

2010

Trials

2 trial(s) available for methotrexate and Deafness, Transitory

Article	Year
Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin. The oncologist, 2018, Volume: 23, Issue:7 Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Cross-Over Studies; Doxorubicin; Female; Hearing; Hearing Loss; Humans; Kidney; Male; Methotrexate; Organic Cation Transporter 2; Osteosarcoma; Pantoprazole; Young Adult	2018
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults. Journal of neuro-oncology, 1998, Volume: 39, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Deafness; Disease Progression; Disease-Free Survival; Etoposide; Follow-Up Studies; Glioma; Hearing Loss; Hematologic Diseases; Humans; Ifosfamide; Infections; Life Tables; Lomustine; Medulloblastoma; Methotrexate; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Vincristine	1998

Article

Year

Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin.

The oncologist, 2018, Volume: 23, Issue:7

Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Cross-Over Studies; Doxorubicin; Female; Hearing; Hearing Loss; Humans; Kidney; Male; Methotrexate; Organic Cation Transporter 2; Osteosarcoma; Pantoprazole; Young Adult

2018

Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.

Journal of neuro-oncology, 1998, Volume: 39, Issue:1

Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Deafness; Disease Progression; Disease-Free Survival; Etoposide; Follow-Up Studies; Glioma; Hearing Loss; Hematologic Diseases; Humans; Ifosfamide; Infections; Life Tables; Lomustine; Medulloblastoma; Methotrexate; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Vincristine

1998

Other Studies

4 other study(ies) available for methotrexate and Deafness, Transitory

Article	Year
Efficiency of antioxidant Avenanthramide-C on high-dose methotrexate-induced ototoxicity in mice. PloS one, 2022, Volume: 17, Issue:3 Topics: Animals; Antioxidants; Apoptosis; Cell Line; Cisplatin; Hearing Loss; Methotrexate; Mice; ortho-Aminobenzoates; Ototoxicity; Reactive Oxygen Species	2022
Is Methotrexate Ototoxic? Investigating the Ototoxic Late Effects of Pediatric Cancer Treatment. American journal of audiology, 2023, Sep-06, Volume: 32, Issue:3 Topics: Antineoplastic Agents; Child; Cisplatin; Deafness; Hearing Loss; Humans; Methotrexate; Neoplasms; Ototoxicity; Retrospective Studies	2023
Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy. Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:2 Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Brain; Brain Diseases; Female; Hearing Loss; Humans; Ifosfamide; Magnetic Resonance Imaging; Methotrexate; Osteosarcoma	2014
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89). Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug Substitution; Etoposide; Female; Follow-Up Studies; Hearing Loss; Humans; Ifosfamide; Kidney Diseases; Leucovorin; Male; Methotrexate; Osteosarcoma; Pilot Projects; Stroke Volume; Survival Rate; Treatment Outcome; Young Adult	2015